Q&A: Pfizer's Mao Mao on Using Next-Generation Sequencing in Drug Development

Recently, Mao Mao, a research fellow at Pfizer Oncology Research who is working on several different cancer sequencing projects, spoke to In Sequence about the company's use of sequencing in drug development and the hurdles that still remain in implementing the technology in pharmaceutical research.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.